SLC5A2 and type 2 diabetes mellitus: Notably, sodium–glucose cotransporter 2 (SGLT2) inhibitors have shown favorable effects on kidney and cardiovascular outcomes in large-scale clinical trials involving patients with type 2 diabetes (Wanner et al., 2016; Neal et al., 2017; Perkovic et al., 2019; Wiviott et al., 2019).